Jeff Yass’s Dianthus Therapeutics DNTH Stock Holding History

Jeff Yass’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12M	Sell	73,000 -68,700	-48%	-$6M	﹤0.01%	3958
2026 Q1	$11.9M	Buy	141,700 +120,000	+553%	+$6.95M	﹤0.01%	2859
2025 Q4	$894K	Sell	21,700 -151,500	-87%	-$5.87M	﹤0.01%	7435
2025 Q3	$6.82M	Buy	173,200 +147,500	+574%	+$3.77M	﹤0.01%	3601
2025 Q2	$479K	Sell	25,700 -55,900	-69%	-$1.05M	﹤0.01%	9274
2025 Q1	$1.48M	Buy	+81,600	New	+$1.8M	﹤0.01%	6247
2021 Q2	–	Sell	-963	Closed	-$182K	–	12673
2021 Q1	$182K	Sell	963 -331	-26%	-$55.7K	﹤0.01%	11501
2020 Q4	$162K	Buy	1,294 +500	+63%	+$56.7K	﹤0.01%	10208
2020 Q3	$86K	Sell	794 -150	-16%	-$17.8K	﹤0.01%	9996
2020 Q2	$113K	Buy	+944	New	+$133K	﹤0.01%	9434

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Jeff Yass's DNTH Position: Q2 2026 in Review

Jeff Yass reduced its Dianthus Therapeutics (DNTH) stake by 62% in Q2 2026, selling an estimated $4.35M and leaving 30,237 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #5664.

Jeff Yass first reported a position in DNTH in Q3 2019 and has held it in 18 quarters since. The position peaked at $6.71M in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Jeff Yass held 30,237 shares of Dianthus Therapeutics worth $2.95M as of Q2 2026.
Jeff Yass sold 49,764 Dianthus Therapeutics shares in Q2 2026, an estimated $4.35M.
Dianthus Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5664 holding.
Jeff Yass first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 18 quarters since.
Jeff Yass's Dianthus Therapeutics position peaked at $6.71M in Q1 2026.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.